Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.

Selpercatinib significantly improves 2-year event-free survival in early-stage RET fusion-positive NSCLC, reaching 92% in stage II/IIIA patients compared to 61% with placebo.

• Why it matters: Early-stage RET fusion-positive NSCLC patients lack targeted adjuvant therapies, and improving outcomes could reduce recurrence and progression risks, filling a critical treatment gap.
• What they did: A phase 3, double-blind trial assigned 151 patients with RET fusion-positive NSCLC to receive up to 3 years of adjuvant selpercatinib or placebo, assessing event-free survival over a median follow-up of 24-27 months.
• The result: Selpercatinib markedly extended event-free survival, with 94% at 2 years across stages IB-IIIA, and demonstrated an acceptable safety profile, supporting its use as an adjuvant therapy in this population.